SAFETY AND EFFICACY OF DIRECT ACTING ANTIVIRALS FOR CHRONIC HEPATITIS C IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON MAINTENANCE HEMODIALYSIS-Reference-Cited by-同舟云学术

SAFETY AND EFFICACY OF DIRECT ACTING ANTIVIRALS FOR CHRONIC HEPATITIS C IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON MAINTENANCE HEMODIALYSIS

Published:2022-06-15 Issue: Volume: Page:71-72
ISSN:
Container-title:PARIPEX INDIAN JOURNAL OF RESEARCH
language:en
Short-container-title:PIJR

Author:

Kumar V Pradeep¹,R Ramani²,M Kannan³,Shankar C Vijai⁴,P. B Sriram⁴

Affiliation:

1. Department Of Medical Gastroenterology, Madurai Medical College.

2. Associate Professor, Department Of Medical Gastroenterology, Madurai Medical College

3. Head Of The Department, Department Of Medical Gastroenterology, Madurai Medical College.

4. Assistant Professor, Department Of Medical Gastroenterology, Madurai Medical College.

Abstract

BACKGROUND AND AIMS: Hepatitis C virus (HCV) infection is common among hemodialysis (HD) patients and is associated with increased morbidity and mortality. Aim of the study is to assess the safety and efficacy of pangenotypic DAA regimens in patients with chronic disease on maintenance hemodialysis. In thisMATERIALS AND METHODS: prospective observational study, hemodialysis patients with chronic hepatitis C infection were identified and treatment initiated with appropriate pangenotypic regimen. Totally 74 patients diagnosed with chronic hepatitis C and treated with DAAs for 12 weeks. The sustained virologic response (SVR) rate obtained 12 weeks post-treatment (SVR12) was evaluated. Laboratory indices and adverse reactions during the treatment process were also assessed. All theRESULTS: patients enrolled completed 12 weeks of treatment. 12 out of 74(16.2%) patients had compensated liver disease. SVR was achieved in 12 out of 12 patients (100%) receiving sofosbuvir/velpatasvir, and 60 of 62 patients (96.7%) receiving sofosbuvir/daclatasvir. No serious or significant adverse reactions were reported. PangenotypicCONCLUSION: regimens containing sofosbuvir are safe and well tolerated in patients with chronic kidney disease on maintenance hemodialysis. Sofosbuvir/daclatasvir based regimens at full dose can be used as an alternative pan genotypic regimen in patients with chronic kidney disease on hemodialysis.

Publisher

World Wide Journals

Reference13 articles.

1. Fabrizi F, Dixit V, Messa P. Hepatitis C virus and mortality among patients on dialysis: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2019; 43:244-254.

2. Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461-511.

3. Collier S, Davenport A. Reducing the risk of infection in end-stage kidney failure patients treated by dialysis. Nephrol Dial Transplant 2014;29: 2158–61.

4. Khaliq S, Raza SM. Current status of direct acting antiviral agents against hepatitis C virus infection in Pakistan. Medicina (Kaunas) 2018;54:80.

5. Frisk P, Aggefors K, Cars T, et al. Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden. Eur J Clin Pharmacol 2018;74:971–8.